'Appalled' Lundbeck appeals European Commission's pay for delay fine
This article was originally published in SRA
Executive Summary
Lundbeck is appealing against the European Commission's "erroneous" decision to fine the Danish pharmaceutical firm €93.8m for breaching competition law1. The company hopes the appeal will shed light on what it claims are "legal and factual errors" by the commission and mark an important legal precedent for other firms navigating Europe's complex patent system.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.